Find an Article

Filter articles

Applied Filters

Showing 251 to 260 of 334 results

Digital health: Issues of patentability

US16-06-2015Marsha Gillentine and Michelle Holoubek

Recent changes in US patent law have made protecting and enforcing patents directed to digital healthcare inventions more challenging, as Marsha Gillentine and Michelle Holoubek of Sterne, Kessler, Goldstein & Fox explain.

TPP: Coming into line


As far we know, the IP chapter in the proposed Trans-Pacific Partnership agreement contains provisions on modernising plant breeders’ rights, but not all the participating countries are currently on the same page, as LSIPR reports.

Preview: 2015 BIO International Convention


LSIPR picks five sessions IP professionals won’t want to miss at this year’s BIO International Convention in Philadelphia, from June 15 to 18.

Gilead: Treating the seven million


Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more.

New players on the patent chess board

US14-05-2015Marc Cavan and Phillip Kurs

The ability of third parties to participate in patent challenges has led to new dynamics, including the possibility of parties profiting from movements in stock price and the prospect of patent oppositions by not-for-profit proxies, as Marc Cavan and Phillip Kurs of law firm Ropes & Gray describe.

Preview: Practical Law’s Life Sciences Forum

International, UK12-05-2015

LSIPR takes a look at what the Practical Law Life Sciences Forum, due to take place on June 25, has to offer.

The patent ‘troll’ tide is turning

International, US07-05-2015Jay Nuttall

Many NPEs have been using their well-stocked war chests to build massive patent portfolios in the medical technology sector, so right owners need to be prepared for a fresh wave of litigation. Jay Nuttall of Steptoe & Johnson offers some tips.

Toxic traces of autumn: will exDNA make it from the forest floor to the pharmacy shelf?

International, US16-04-2015Charles Brabin

A product of decomposing leaf litter, exDNA could be a powerful tool for interacting with biological systems. If so, the IP associated with its applications may be an active area in the coming years, says non-practising barrister Charles Brabin.

Divergent patent pathways

US02-04-2015Joachim Wachenfeld and Oswin Ridderbusch

There are important differences between the EPO and the USPTO in the assessment of patentable subject matter in life sciences. Depending on the technology involved, patentees may elect national or regional applications as a useful alternative to PCT filings, as Joachim Wachenfeld and Oswin Ridderbusch explain.

I won’t dance, so don’t ask me

US12-03-2015Andrew Williams

In the battle for marketing approval of a biosimilar version of Neupogen under the BPCIA, applicant Sandoz stymied Amgen’s chance to join the so-called patent dance. Andrew Williams of McDonnell Boehnen Hulbert & Berghoff ponders the implications.

Showing 251 to 260 of 334 results